My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 144

    1.

    Agomelatine treatment of major depressive disorder.

    Dolder CR, Nelson M, Snider M.

    Ann Pharmacother. 2008 Dec;42(12):1822-31. Epub 2008 Nov 25. Review.PMID: 19033480 [PubMed - indexed for MEDLINE]Related articles

    2.

    Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.

    Kasper S, Hamon M.

    World J Biol Psychiatry. 2009;10(2):117-26. Review.PMID: 19255935 [PubMed - indexed for MEDLINE]Related articles

    3.

    Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.

    Lôo H, Hale A, D'haenen H.

    Int Clin Psychopharmacol. 2002 Sep;17(5):239-47.PMID: 12177586 [PubMed - indexed for MEDLINE]Related articles

    4.

    Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.

    Olié JP, Kasper S.

    Int J Neuropsychopharmacol. 2007 Oct;10(5):661-73. Epub 2007 May 4.PMID: 17477888 [PubMed - indexed for MEDLINE]Related articles

    5.

    Clinical efficacy of agomelatine in depression: the evidence.

    den Boer JA, Bosker FJ, Meesters Y.

    Int Clin Psychopharmacol. 2006 Feb;21 Suppl 1:S21-4.PMID: 16436936 [PubMed - indexed for MEDLINE]Related articles

    6.

    [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders]

    Lôo H, Daléry J, Macher JP, Payen A.

    Encephale. 2002 Jul-Aug;28(4):356-62. French. PMID: 12232545 [PubMed - indexed for MEDLINE]Related articles

    7.

    Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.

    Lemoine P, Guilleminault C, Alvarez E.

    J Clin Psychiatry. 2007 Nov;68(11):1723-32.PMID: 18052566 [PubMed - indexed for MEDLINE]Related articles

    8.

    Agomelatine: a preliminary review of a new antidepressant.

    Zupancic M, Guilleminault C.

    CNS Drugs. 2006;20(12):981-92. Review.PMID: 17140278 [PubMed - indexed for MEDLINE]Related articles

    9.

    Treating each and every depressed patient.

    Kennedy SH.

    J Psychopharmacol. 2008 Sep;22(7 Suppl):19-23. Review.PMID: 18753279 [PubMed - indexed for MEDLINE]Related articles

    10.

    [Use of antidepressant drugs in schizophrenic patients with depression]

    Micallef J, Fakra E, Blin O.

    Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French. PMID: 16910628 [PubMed - indexed for MEDLINE]Related articles

    11.

    Efficacy and tolerance profile of agomelatine and practical use in depressed patients.

    Rouillon F.

    Int Clin Psychopharmacol. 2006 Feb;21 Suppl 1:S31-5.PMID: 16436938 [PubMed - indexed for MEDLINE]Related articles

    12.

    [Antipsychotics in bipolar disorders]

    Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

    Encephale. 2004 Sep-Oct;30(5):417-24. Review. French. PMID: 15627046 [PubMed - indexed for MEDLINE]Related articles

    13.

    Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.

    Goodwin GM, Emsley R, Rembry S, Rouillon F; Agomelatine Study Group.

    J Clin Psychiatry. 2009 Aug;70(8):1128-37. Epub 2009 Aug 11.PMID: 19689920 [PubMed - indexed for MEDLINE]Related articles

    14.

    Melatonergic drugs in clinical practice.

    Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP.

    Arzneimittelforschung. 2008;58(1):1-10. Review.PMID: 18368944 [PubMed - indexed for MEDLINE]Related articles

    15.

    Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.

    Stein DJ, Ahokas AA, de Bodinat C.

    J Clin Psychopharmacol. 2008 Oct;28(5):561-6.PMID: 18794654 [PubMed - indexed for MEDLINE]Related articles

    16.

    [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders]

    Lôo H, Daléry J, Macher JP, Payen A.

    Encephale. 2003 Mar-Apr;29(2):165-71. French. PMID: 14567168 [PubMed - indexed for MEDLINE]Related articles

    17.

    Agomelatine: efficacy at each phase of antidepressant treatment.

    Kennedy SH.

    CNS Drugs. 2009;23 Suppl 2:41-7. doi: 10.2165/11318660-000000000-00000. Review.PMID: 19708725 [PubMed - indexed for MEDLINE]Related articles

    18.

    Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine.

    Montgomery SA, Kasper S.

    Int Clin Psychopharmacol. 2007 Sep;22(5):283-91.PMID: 17690597 [PubMed - indexed for MEDLINE]Related articles

    19.

    Agomelatine, an innovative pharmacological response to unmet needs.

    Le Strat Y, Gorwood P.

    J Psychopharmacol. 2008 Sep;22(7 Suppl):4-8. Review.PMID: 18753276 [PubMed - indexed for MEDLINE]Related articles

    20.

    Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.

    Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS.

    Ann Intern Med. 2005 Sep 20;143(6):415-26. Review.PMID: 16172440 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity